Paul Rhodes, PhD
Co-Founder & Chief Executive Officer
Dr. Rhodes defines the vision for Specific’s novel and important applications, and leads the identification and development of the company’s most important collaborative clinical relationships. Dr. Rhodes also established Specific’s first overseas office in the BioData Innovation Centre on the grounds of the Wellcome Trust Genome Campus, which houses the Sanger Institute.
Prior to Specific, Dr. Rhodes founded Evolved Machines, where he was PI for the DARPA RealNose program, directing a team of 8 universities and corporations to deliver an end-to-end artificial olfaction device capable of canine-competitive sensitivity in real-world conditions, which fostered development of Specific’s fundamental technology, which can be considered a form of artificial olfaction. During this project Dr. Rhodes oversaw the successful development of the first integrated nanotube FET sensor array, along with advances in the engineering of the Suslick sensor that is the heart of the Specific’s products. Dr. Rhodes’ received an AB in Physics magna cum laude from Harvard University, an MS in Physics from Stanford University, and a PhD in Neuroscience from NYU Medical School.
Co-Founder & Chief Operations Officer
Ray Martino is COO and a co-founder of Specific Diagnostics. Ray has contributed in both technical and business capacities as Specific moved from research through product development on to the commercial stage.
Previously Ray was General Manager of the mobile and wireless business division at Symbol Technologies where he held various roles as the company grew from under $20M in sales to over $2B before being acquired by Motorola in 2007, after which Ray was CTO of Motorola’s enterprise business. As a pioneer of mobile computers and WiFi, Ray led the engineering, marketing and sales teams that were the creators and first go-to-market WiFi products including many first-in-the-world, category-creating products including: the world’s first mobile computer with a wireless network (long before iPhones), the world’s first wireless network switch and the world’s first commercial wearable mobile computing system.
Chief Commercial Officer
Tony Bazarko has served as Chief Commercial Officer of Specific Diagnostics since October of 2020. Prior to joining Specific Dx he most recently held the position of Vice President, Commercial Development for the Americas and the General Manager of Canada at Danaher Corporation’s subsidiary Leica Biosystems. Mr. Bazarko Joined Leica as the Vice President of Sales in 2016.
Prior to Danaher, Mr. Bazarko held the positions of Senior Director, Strategic Affairs for North America and Senior Director of the Commercial Sales and Marketing for Life Science division at Roche Diagnostics Corporation. Mr. Bazarko also served in various leadership roles at Life Technologies and Fisher Scientific International. Mr. Bazarko holds a B.S. in Biology from Indiana University and his M.B.A from Northwestern’s Kellogg School of Management.